Lilly immunology portfolio to be featured in 16 presentations
INDIANAPOLIS, June 7, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that radiographic results from a long-term extension study of baricitinib, RA-BEYOND, and patient-reported outcomes data from baricitinib's phase 3 global studies will be presented, along with other phase 2b and preclinical studies, at the Annual European Congress of Rheumatology (EULAR 2016) in London, June 8-11, 2016.
"We look forward to presenting new data from our immunology portfolio at the Annual European Congress of Rheumatology (EULAR 2016)," said J. Anthony Ware, M.D., senior vice president, product development, Lilly Bio-Medicines. "Lilly is committed to developing the next generation of treatments, especially for people with rheumatoid arthritis and psoriatic arthritis because these patients deserve new alternative treatment options."
Highlighted presentations and posters include:
Baricitinib Data
Thursday, June 9, 2016, 11:45am - 1:30pm BST – POSTER PRESENTATIONS
Friday, June 10, 2016, 11:10am - 11:20am BST – ORAL PRESENTATION
Friday, June 10, 2016, 11:15am - 1:30pm BST – POSTER PRESENTATION
Ixekizumab Data
Thursday, June 9, 2016, 11:45am - 1:30pm BST – POSTER PRESENTATIONS
Friday, June 10, 2016, 10:30am - 10:40am BST – ORAL PRESENTATION
About Baricitinib
Baricitinib is a once-daily oral highly selective JAK1 and JAK2 inhibitor currently in late-stage clinical studies for inflammatory and autoimmune diseases. There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases, suggesting that JAK inhibitors may be useful for the treatment of a broad range of inflammatory conditions. Baricitinib demonstrates approximately 100-fold greater potency of inhibition against JAK1 and JAK2 than JAK3 in kinase assays.
In December 2009, Lilly and Incyte announced an exclusive worldwide license and collaboration agreement for the development and commercialization of baricitinib and certain follow-on compounds for patients with inflammatory and autoimmune diseases. Baricitinib was submitted for regulatory review seeking marketing approval for the treatment of rheumatoid arthritis in the U.S., European Union and Japan in Q1 2016, and is being studied in phase 2 trials for atopic dermatitis and systemic lupus erythematosus.
About Rheumatoid Arthritis
Rheumatoid arthritis is an autoimmune disease characterized by inflammation and progressive destruction of joints.[i,ii] More than 23 million people worldwide suffer from RA.[iii] Approximately three times as many women as men have the disease. Current treatment of RA includes the use of non-steroidal anti-inflammatory drugs, oral conventional disease-modifying antirheumatic drugs (cDMARDs), such as methotrexate – the current standard of care – and injectable, biological disease-modifying antirheumatic drugs (bDMARDs) that target selected mediators implicated in the pathogenesis of RA.[iv] Despite current treatment options, many patients do not reach their therapeutic goals or sustained remission.[v,vi] There remains an important need to provide additional treatments to improve overall patient care.
About Ixekizumab
Ixekizumab is a humanised IgG4 monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. [vii] IL-17A is a naturally occuring cytokine that is involved in normal inflammatory and immune responses. [vii] Ixekizumab inhibits the release of pro-inflammatory cytokines and chemokines.[ix] Ixekizumab is in clinical development for the treatment of psoriatic arthritis and axial spondlyoarthritis.
About Psoriatic Arthritis
Psoriatic arthritis is a chronic, progressive form of inflammatory arthritis that can cause swelling, stiffness and pain in and around the joints, nail changes and impaired physical function. If left untreated, psoriatic arthritis can cause permanent joint damage. Up to 30 percent of people with psoriasis also develop psoriatic arthritis.[x]
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and newsroom.lilly.com/social-channels.
(P-LLY)
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about baricitinib as a treatment for rheumatoid arthritis and ixekizumab as a treatment for psoriatic arthritis, and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with study findings to-date, or that baricitinib or ixekizumab will receive regulatory approvals or prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent 10-K and 10-Q filings with the United States Securities and Exchange Commission. Except as may be required by law, Lilly undertakes no duty to update forward-looking statements for events occurring after the date of this release.
i American College of Rheumatology, Rheumatoid Arthritis, http://www.rheumatology.org/practice/clinical/patients/diseases_and_conditions/ra.asp (Accessed: May 16, 2016)
ii Hand Clinics, Advances in the Medical Treatment of Rheumatoid Arthritis, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3135413/pdf/nihms305780.pdf (Accessed: May16, 2016)
iii WHO Global Burden of Disease Report, (table 7, page 32) 2004, http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf (Accessed May 16, 2016)
iv Arthritis Foundation, Medications for Rheumatoid Arthritis, http://www.arthritistoday.org/about-arthritis/types-of-arthritis/rheumatoid-arthritis/treatment-plan/medication-overview/ra-medications.php (Accessed: May 16, 2016)
v Rheumatoid arthritis, Lancet, https://www.ncbi.nlm.nih.gov/pubmed/27156434 (Accessed: May 19, 2016)
vi Sustained rheumatoid arthritis remission is uncommon in clinical practice, Arthritis Research & Therapy, http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446437/ (Accessed: May 19, 2016)
vii Data on File. Eli Lilly and Company; 2015
viii Moderate to severe psoriasis and psoriatic arthritis: biologic drugs. National Psoriasis Foundation website
ix Lønnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clinical, Cosmetic and Investigational Dermatology. 2014;7:251-259.doi:10.2147/CCID.S67534
x About psoriatic arthritis. National Psoriasis Foundation website. https://www.psoriasis.org/about-psoriatic-arthritis (Accessed: May 16, 2016)
|
Refer to: |
Nan Frient; frient_nan@lilly.com; +1-317-471-7040 (Lilly media) |
|
Phil Johnson; johnson_philip_l@lilly.com; +1-317-655-6874 (investors) |
Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO
SOURCE Eli Lilly and Company